Philippe Lam, MD
Internal Medicine · Las Vegas, NVNPI 1417243684
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $962 of the $1,456 with a category attached, or 66.0%. Encore Medical, LP accounts for 66.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $1,231 and has fallen 87.2% since, to $157 in 2025.
Across 29 payments — averaging $50.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Encore Medical, LP$962
- Exact Sciences$133
- Lilly USA, LLC$79
- Johnson & Johnson$70
- GSK$49
- AstraZeneca$31
- plus $133 from 6 others
What the payments were for
- Travel & lodging$96266%
- Food & beverage$43030%
- Education$644%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Encore Medical, LP | 4 | $962 |
| Exact Sciences | 7 | $133 |
| Lilly USA, LLC | 3 | $79 |
| Johnson & Johnson | 4 | $70 |
| GSK | 3 | $49 |
| AstraZeneca | 2 | $31 |
| Amgen | 1 | $29 |
| Abbott | 1 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Pfizer | 1 | $18 |
| Next Science LLC | 1 | $16 |
| Novo Nordisk | 1 | $15 |
How this compares
$1,456 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $126,994 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 134 | $125,575 |
| TrulicityDulaglutide | 49 | $106,777 |
| RybelsusSemaglutide | 45 | $103,692 |
| FarxigaDapagliflozin Propanediol | 42 | $64,810 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $45,256 |
| XareltoRivaroxaban | 31 | $41,593 |
| MounjaroTirzepatide | 28 | $39,279 |
| OzempicSemaglutide | 16 | $29,897 |
| VemlidyTenofovir Alafenamide | 19 | $29,787 |
| JardianceEmpagliflozin | 17 | $28,544 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $20,577 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,485 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $7,728 |
| Atorvastatin Calcium | 1,048 | $7,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $79 | $146,05677 claims |
| Novo NordiskRybelsus, Ozempic | $15 | $133,58961 claims |
| PfizerEliquis | $18 | $126,99472 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $31 | $93,11471 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $49 | $54,74051 claims |
| Johnson & JohnsonXarelto | $70 | $41,59331 claims |
| Boehringer IngelheimJardiance | $26 | $28,54417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.